Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy

Epilepsy and Behavior

Volumn 15, Issue 2, 2009, Pages 154-159

  Carreño, Mar ^a   Donaire, Antonio ^a   Falip, Mercè ^a   Maestro, Iratxe ^a   Fernández, Santiago ^a   Nagel, Antonio Gil ^b   Serratosa, Jose ^c   Salas, Javier ^d   Viteri, César ^e   Llorens, Jordi ^f   Baró, Eva ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL RUBER INTERNACIONAL   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d Oviedo Hospital   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f UCB PHARMA   (Belgium)

^g 3D Health Research   (Spain)

Author keywords

Adverse effects; Epilepsy; Feasibility; Profile; Questionnaire; Reliability; Scale; Validation; Validity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; VALPROIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EPILEPSY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTERNAL CONSISTENCY; LIVERPOOL ADVERSE EVENTS PROFILE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PSYCHOMETRY; QUALITY OF LIFE; SCORING SYSTEM; SPAIN; TEST RETEST RELIABILITY; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ADULT; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OBSERVATION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; TRANSLATING;

EID: 67349143229     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.11.016     Document Type: Article

References (27)

1. Gilliam F., Carter J., and Vahle V. Tolerability of anti-seizure medications: implications for health outcomes. Neurology 63 (2004) S9-S12
2. Forsgren L., Beghi E., and Oun A. Sillanpää: the epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol 12 (2005) 245-253
3. Luengo A., Parra J., Colas J., et al. Prevalence of epilepsy in northeast Madrid. J Neurol 248 (2001) 762-767
4. Fernandes P., Salgado P.C.B., Noronha A.L.A., and Sander J.W. Stigma scale of epilepsy: validation process. Arq Neuropsiquiatr 65 Suppl. 1 (2007) 35-42
5. Szaflarski M., Meckler J.M., Privitera M.D., and Szaflarski J.P. Quality of life in medication-resistant epilepsy: the effects of patient's age, age at seizure onset and disease duration. Epilepsy Behav 8 (2006) 547-551
6. Berto P. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 20 (2002) 1039-1059
7. Hermann B.P., Vickrey B., Hays R.D., et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 25 (1996) 113-118
8. Kaminow L., Schimschok J.R., Hammer A.E., and Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin or valproate monotherapy in patients with epilepsy. Epilepsy Behav 4 (2003) 659-666
9. Baker G.A., Jacoby A., Buck D., Stalgis C., and Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 38 (1997) 353-362
10. Gilliam F.G., Fesler J.A., Baker G., et al. Systematic screening allows reduction of adverse antiepileptic drugs effects: a randomized trial. Neurology 62 (2004) 23-27
11. Torres X., Arroyo S., Araya S., and de Pablo J. Adaptación del Quality of Life in Epilepsy Inventory (QOLIE-31): traducción, validez y fiabilidad. Rev Psiquiatría Fac Med Barna 27 (2000) 406-413
12. Baker G.A., Frances P., and Middleton E. Initial development, reliability, and validity of a patient-based adverse events scale. Epilepsia 35 (1994) 80
13. Baker G.A., Camfield C., Camfield P., et al. Commission on outcome measurement in epilepsy. Epilepsia 39 (1998) 213-231
14. Gilliam F., Carter J., and Vahle V. Tolerability of antiseizure medications: implications for health outcomes. Neurology 63 (2004) S9-S12
15. Panelli R.J., Kilpatrick C., Moore S.M., et al. The Liverpool Adverse Events Profile: relation to AED use and mood. Epilepsia 48 (2007) 456-463
16. Hasnaouis A., Crespel A., Daures J.P., Baldy-Moulinier M., and Picot M.C. Psychometric validation of the French version of the Side Effects and Life Satisfaction inventory (SEALS) in epileptic patients: comparison with the QOLIE-31 inventory and a generic quality of life questionnaire. Epileptic Disord 7 (2005) 103-113
17. Herdman M., Fox-Rushby J., and Badia X. 'Equivalence' and the translation and adaptation of health-related quality of life questionnaires. Qual Life Res 6 (1997) 237-247
18. Vickrey B.G., Perrine K.R., Hays R.D., et al. Quality of life in epilepsy QOLIE-31 (Version 1.0): scoring manual and patient inventory (1993), Rand, Santa Monica, CA
19. Herrero M., Blanch J., Peri J.M., et al. A validation study of the Hospital Anxiety and Depression Scale (HADS) in Spanish population. Gen Hosp Psychiatry 25 (2003) 277-283
20. Hermann C. International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 42 (1997) 17-41
21. Streiner D.L., and Norman G.R. Health Measurement Scales: a practical guide to their development and use. 2nd ed. (1995), Oxford University Press, Oxford
22. Nunnally J., and Bernstein I.H. Psychometric theory. 3rd ed. (1994), McGraw-Hill, New York
23. Langfitt J., and Meador K. Want to improve epilepsy care? Ask the patient. Neurology 62 (2004) 6-7
24. Uijl S.G., Uiterwaal C.S., Aldenkamp A.P., et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 15 (2006) 242-248
25. Carreño M., Gil-Nagel A., Sánchez J.C., et al. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav 13 (2008) 178-183
26. McHorney C.A., and Tarlov A.R. Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res 4 (1995) 293-307
27. Selai C., Bannister D., and Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 46 Suppl. 4 (2005) 50-57